TY - JOUR. T1 - SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. AU - Jones, K. B.. AU - Su, L.. AU - Jin, H.. AU - Lenz, C.. AU - Randall, R. AU - Underhill, T. M.. AU - Nielsen, T. O.. AU - Sharma, S.. AU - Capecchi, M. R.. PY - 2013/5/2. Y1 - 2013/5/2. N2 - Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly ...
TY - JOUR. T1 - Biphasic synovial sarcomas arising in the pleural cavity. T2 - A clinicopathologic study of five cases. AU - Gaertner, Erich. AU - Zeren, E. Handan. AU - Fleming, Marian V.. AU - Colby, Thomas V.. AU - Travis, William D.. PY - 1996/1. Y1 - 1996/1. N2 - Five cases of primary synovial sarcoma of the pleura are presented with a discussion of differentiation from other biphasic malignant neoplasms, most notably malignant mesothelioma. The cases have clinical, histologic, and immunohistochemical features consistent with synovial sarcoma of soft tissue. The average age at initial presentation of the reported patients was 25 years with an approximate range of 9 to 50 years. A large pleural-based intrathoracic mass was identified in each case. Histologic analysis showed a biphasic (mixed) pattern composed of epithelial and spindle cells. The epithelial cells showed cleft-like to tubulopapillary growth with focal intraluminal periodic acid Schiffs (PAS)-positive, diastase-resistant ...
... Synovial sarcomas are a rare subset of malignant soft tissue tumors, with an estimated incidence of 2.75 p..
Dermatopathology reference describes biphasic synovial sarcoma histopathology including histologic features and provides links to additional medical references.
Tissue samples and cell lines. Tumor tissues were obtained at either biopsy or resection surgery and kept at −80°C. Informed consent was obtained from each patient, and tumor samples were approved for analysis by the Ethics Committee of the Faculty of Medicine, Kyoto University. Five human synovial sarcoma cell lines (YaFuSS, HS-SY-II, SYO-1, Fuji, and 1273/99) were used in this study. YaFuSS and HS-SY-II cells have the SYT-SSX1 fusion gene and the others have the SYT-SSX2 fusion gene (data not shown). YaFuSS was established in our laboratory from a monophasic synovial sarcoma in a 28-year-old male. HS-SY-II was a gift from H. Sonobe (Kochi University, Japan; ref. 18), SYO-1 from A. Kawai (Okayama University, Japan; ref. 19), Fuji from S. Tanaka (Hokkaido University, Japan; ref. 20), and 1273/99 from O. Larsson (Karolinska Institute, Sweden). Among control cell lines, NMS-2 (malignant peripheral nerve sheath tumor; ref. 21) was provided by A. Ogose (Niigata University, Japan), and Saos2 ...
A synovial sarcoma (also known as: malignant synovioma) is a rare form of cancer which occurs primarily in the extremities of the arms or legs, often in close proximity to joint capsules and tendon sheaths. It is a type of soft tissue sarcoma. The name "synovial sarcoma" was coined early in the 20th century, as some researchers thought that the microscopic similarity of some tumors to synovium, and its propensity to arise adjacent to joints, indicated a synovial origin; however, the actual cells from which the tumor develops are unknown and not necessarily synovial. Primary synovial sarcomas are most common in the soft tissue near the large joints of the arm and leg but have been documented in most human tissues and organs, including the brain, prostate, and heart. Synovial sarcoma occurs in about 2 per 100,000 people a year. They occur most commonly in the third decade of life, with males being affected more often than females (ratio around 1.2:1). Synovial sarcoma usually presents with an ...
Conventional cytotoxic therapies for synovial sarcoma provide limited benefit, and no drugs specifically targeting the causative SS18-SSX fusion oncoprotein are currently available. Histone deacetylase (HDAC) inhibition has been shown in previous studies to disrupt the synovial sarcoma oncoprotein complex, resulting in apoptosis. To understand the molecular effects of HDAC inhibition, RNA-Seq transcriptome analysis was undertaken in six human synovial sarcoma cell lines. HDAC inhibition induced pathways of cell cycle arrest, neuronal differentiation and response to oxygen-containing species, effects also observed in other cancers treated with this class of drugs. More specific to synovial sarcoma, polycomb-group targets were reactivated including tumor suppressor CDKN2A, and pro-apoptotic transcriptional patterns were induced. Functional analyses revealed that ROS-mediated FOXO activation and pro-apoptotic factors BIK, BIM and BMF were important to apoptosis induction following HDAC-inhibition ...
Using synovial sarcoma as a prototype tumor with specific chromosomal translocation and the resultant gene fusion, we generated four synthetic peptides from the SYT-SSX fusion gene according to the HLA-A24 binding motif. We found that one or more of these four peptides reacted in the context of HLA-A24/peptide tetramer with 0.25% or more of circulating CTLps in six (66.7%) of nine synovial sarcoma patients who had either a present or past history of pulmonary metastasis, whereas such high CTLp frequency was detected in none of seven synovial sarcoma patients without metastasis, in 1 of 10 patients with other sarcomas, and in none of the 10 healthy individuals. The specificity of the CTLp to the SYT-SSX sequence was confirmed in three synovial sarcoma patients by using an HLA-A24/Recoverin peptide tetramer. These findings suggest that aberrantly expressed SYT-SSX gene products have primed SYT-SSX-specific CTLps in vivo and increased their frequency in synovial sarcoma patients, especially during ...
Fusion of the SS18 and either one of the SSX genes is a hallmark of human synovial sarcoma. The SS18 and SSX genes encode nuclear proteins that exhibit opposite transcriptional activities. The SS18 protein functions as a transcriptional coactivator and is associated with the SWI/SNF complex, whereas the SSX proteins function as transcriptional corepressors and are associated with the polycomb complex. The domains involved in these opposite transcriptional activities are retained in the SS18-SSX fusion proteins. Here, we set out to determine the direct transcriptional consequences of conditional SS18-SSX2 fusion protein expression using complementary DNA microarray-based profiling. By doing so, we identified several clusters of SS18-SSX2-responsive genes, including a group of genes involved in cholesterol synthesis, which is a general characteristic of malignancy. In addition, we identified a group of SS18-SSX2-responsive genes known to be specifically deregulated in primary synovial sarcomas, ...
A synovial sarcoma is a rare form of cancer which occurs primarily in the extremities of the arms or legs, often in close proximity to joint capsules and tendon sheaths. As one of the soft tissue sarcomas, it is one of the rarest forms of soft tissue cancer. SRC signaling is crucial in the growth of
Synovial sarcoma is an aggressive soft-tissue malignancy of children and young adults, with no effective systemic therapies. Its specific oncogene, SYT-SSX (SS18-SSX), drives sarcoma initiation and development. The exact mechanism of SYT-SSX oncogenic function remains unknown. In an SYT-SSX2 transgenic model, we show that a constitutive Wnt/β-catenin signal is aberrantly activated by SYT-SSX2, and inhibition of Wnt signaling through the genetic loss of β-catenin blocks synovial sarcoma tumor formation. In a combination of cell-based and synovial sarcoma tumor xenograft models, we show that inhibition of the Wnt cascade through coreceptor blockade and the use of small-molecule CK1α activators arrests synovial sarcoma tumor growth. We find that upregulation of the Wnt/β-catenin cascade by SYT-SSX2 correlates with its nuclear reprogramming function. These studies reveal the central role of Wnt/β-catenin signaling in SYT-SSX2-induced sarcoma genesis, and open new venues for the development of ...
Special stains: Histochemistry- Secretions within the epithelial cells and pseudoglandular spaces are PAS positive and diastase resistant, alcian blue and mucicarmine positive.. The stromal mucin secreted by the spindle cells are alcian blue positive but PAS negative.. Reticulin stain demonstrate the biphasic pattern of the tumor. Nests of plump rounded cells are highlighted by the reticulin stain.. Immunohistochemistry:. Synovial sarcoma demonstrates nuclear staining with TLE1 (transducin-like enhancer of split-1) in 95% of tumors and appears to be a very sensitive marker. TLE1 encodes for a transcriptional corepressor that is involved in epithelial and neuronal differentiation.. In Synovial sarcoma there is usually coexpression of mesenchymal (vimentin) and epithelial markers (cytokeratin and EMA).. The following immunomarkers are useful in the diagnosis:. - Cytokeratin (+). Only synovial sarcoma is positive with cytokeratins 7 and 19 , other soft tissue sarcomas including synovial sarcoma is ...
Introduction: Previous studies in metastatic soft tissue sarcomas (STS) showed that synovial sarcomas tend to have better survival rates and a higher chemosensitivity than other STS subtypes. However, data are derived from relatively small subgroups and statistical significance of these observations is lacking. Larger cohorts are necessary to define and confirm the specific characteristics of this subtype. Patients and methods: Patient data were retrieved from 15 European Organisation for Research and Treatment of Cancer advanced first-line STS trials. Patient characteristics, survival and treatment response of synovial sarcoma patients were compared to other STS patients. Univariable and multivariable analyses were performed to evaluate prognostic factors. Results: In total, 3330 advanced STS patients were retrieved, of whom 313 had a synovial sarcoma. Synovial sarcoma patients were significantly younger (median 40 versus 52 years), more often had extremity primary tumours and had a better ...
The Synovial Sarcoma Research Foundation funded a three year research project at the University Medical Center St. Radboud Nijmegen, the Netherlands. Research professor was Prof. Dr. Winette van der Graaf.. She was working with her team of colleagues Dr. Yvonne Versleijen-Jonkers (medical oncology) and Dr. Patricia Groenen (Pathology) and the talented researcher Myrella Vlenterie.. The aim of this project was to find new treatment options for patients with synovial sarcoma. The project consisted of two parts.. Part I: Tumor analysis. The first part consists of the analysis of tumor material by Next Generation Sequencing (NGS). With this method the researchers map the genetic makeup of tumors in order to find markers that can predict whether a particular tumor will respond to a particular therapy. They are using the available tumor tissue and cell lines at the St. Radboud as well as cell lines that were supplied by colleagues in Japan.. Part II: Mouse models. The second part consists of the ...
Brodin B, Haslam K, Yang K, Bartolazzi A, Xie Y, Starborg M, Lundeberg J, Larsson O (May 2001). "Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression". Gene. 268 (1-2): 173-82. doi:10.1016/S0378-1119(01)00412-7. PMID 11368913 ...
Soft tissue sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. There are approximately 50 types of soft tissue sarcomas, including synovial sarcoma, a cancer of the connective tissue around joints. The most common locations are the hip, knee, ankle, and shoulder. Synovial sarcoma accounts for approximately 6% to 10% of all soft tissue sarcomas. Approximately one third of synovial sarcomas occur in childhood and the peak incidence is in the third decade of life.. ...
TY - JOUR. T1 - Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. AU - Robbins, Paul F.. AU - Morgan, Richard A.. AU - Feldman, Steven A.. AU - Yang, James C.. AU - Sherry, Richard M.. AU - Dudley, Mark E.. AU - Wunderlich, John R.. AU - Nahvi, Azam V.. AU - Helman, Lee J.. AU - Mackall, Crystal L.. AU - Kammula, Udai S.. AU - Hughes, Marybeth S.. AU - Restifo, Nicholas P.. AU - Raffeld, Mark. AU - Lee, Chyi Chia Richard. AU - Levy, Catherine L.. AU - Li, Yong F.. AU - El-Gamil, Mona. AU - Schwarz, Susan L.. AU - Laurencot, Carolyn. AU - Rosenberg, Steven A.. PY - 2011/3/1. Y1 - 2011/3/1. N2 - Purpose: Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and approximately 25% of patients with melanoma and common ...
Primary renal sarcoma is a rare tumor that accounts for approximately 1% - 3% of malignant renal neoplasms, and leiomyosarcoma is the most common subtype, which accounts for 50% - 60% of all renal sarcomas (3). Primary RSS, a mesenchymal tumor occurring mainly in adults, is an extremely rare neoplasm (3, 4). It was described firstly by Argani et al. in 1999 and since then, approximately 120 cases of RSS have been reported in the literature (2, 5, 6). RSS can be initially misdiagnosed as renal cell carcinoma because of similar clinical characteristics (7). In previous reports, age of RSS patients ranged from 17 to 78 years (median: 36.5 years), and no gender predominance was observed (8, 9). Patients with RSS might be asymptomatic or suffer from abdominal pain, hematuria, fever, and dysuria (10). All sorts of presenting clinical characteristics may arise based on location and size of the lesion.. CT and MRI imaging provided useful information for determining the extent and invasiveness of the ...
Answer: B. Polypoid endometrioma. Histology: A polypoid mass is seen projecting into the urethra. The mass has both solid and cystic components. The cystic components are lined variably by cuboidal cells w/o cilia, cuboidal or columnar cells with cilia, or urothelium. The intervening stroma has the appearance of endometrial stroma with condensation around the cysts. Clusters of prominent thick walled arterioles are evident. The tumor stroma was positive for estrogen receptor, progesterone receptor, and CD10.. Discussion: A characteristic features of spindle cell tumors in the kidney is that they tend to entrap native renal tubules, which then often become cystically dilated. This occurs in monophasic synovial sarcoma, angiomyolipoma, and in mixed epithelial and stromal tumor (MEST). In all these lesions, the tubules are lined by bland cuboidal epithelium which label with PAX8. Another feature of several renal lesions is that the stroma can undergo metaplasia to ovarian-like stroma which ...
The SW 982 cell line was initiated by A. Leibovitz in 1974 at the Scott and White Clinic, Temple, Texas from a surgical specimen of a biphasic synovial sarcoma removed from a 25 year old female Caucasian.
Synovial sarcoma is a cancer that can come from different types of soft tissue, such as muscle or ligaments. One third of patients with synovial sarcoma will be diagnosed under the age of 30. It is somewhat more common in males. Learn more about the tumor, diagnosis, and prognosis from the MyPART project.
Synovial sarcomas of the pericardium are very rare. This report describes the case of a 61-year-old man presenting with increasing dyspnea on exertion and recurrent pericardial effusions. Echocardiography, computed tomography, and magnetic resonance imaging demonstrated a 6 x 4-cm pericardial mass lying predominantly over the left atrium. He was treated by surgical excision with the aid of cardiopulmonary bypass, and a subsequent histological analysis confirmed the diagnosis of a pericardial synovial sarcoma.
A recent publication from Italy talks about the latest approaches to treat synovial sarcoma: http://www.ncbi.nlm.nih.gov/pubmed/24661286 Here are clinical trials that follow those approaches: http://www.clinicaltrials.g…
The study analysed that the Synovial sarcoma pipeline analysis comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to thre...
Radiography is often the initial study obtained for the evaluation of synovial sarcoma. In 50% of patients with synovial sarcoma, radiographic findings are interpreted as normal (as potentially could ... more
Synovial sarcomas are a rare form of slow growing soft tissue cancer that commonly forms around the joints in the arms or legs in adolescent or young adults.
Learn all about synovial cell sarcoma. The name synovial sarcoma was coined early in the 20th century, as some researchers thought that the microscopic s. CancerWORLD Cancer Treatment Research Journal
Synovial Sarcoma consistently harbors t(X;18) resulting in SS18-SSX1, SS18-SSX2 and rarely SS18-SSX4 fusion transcripts. Of 328 cases included in our study, synovial sarcoma was either the primary diagnosis or was very high in the differential diagnosis in 134 cases: of these, amplifiable cDNA was obtained from 131. SS18-SSX fusion products were found in 126 (96%) cases (74 SS18- SSX1, 52 SS18-SSX2), using quantitative and 120 by conventional reverse transcriptase-polymerase chain reaction (RT-PCR). One hundred and one cases in a tissue microarray, analyzed by fluorescence in situ hybridization (FISH), revealed that 87 (86%) showed SS18 rearrangement: four RT-PCR positive cases, reported as negative for FISH, showed loss of one spectrum green signal, and 15 cases had multiple copies of the SS18 gene: both findings are potentially problematic when interpreting results. One of three cases, not analyzed by RT-PCR reaction owing to poor quality RNA, was positive by FISH. SS18-SSX1 was present in 56 ...
It is a type of cancer that is quite rare and is mostly known to begin from the skin or any forms of soft tissue surroundings like in some particular organs. This type of tumor has also some rare occurrence in the bone tissue. The term was coined after the first diagnosis, this is because they appear to be spindle shaped when viewed under a microscope. The determinant factor of this cancer is its formation. They begin in layers of connective tissue and mostly under the skin where two or more muscles connect.. The observation can be determined in various ways and the most obvious way is a small lump that also portrays some inflammation. This inflammation begins to develop slowly by slowly through out every stage.. In the first stage, this lump isnt that noticeable and it is usually self-contained so the probability of cancerous malignant presence could be voted out, however, the naked eye could vote out this aspect but with a close observation of the tumor through a microscope, cancer forms can ...
But first, I feel like I should explain whats been going on with me and why I havent been around. One Thing After Another Back in late December of 2016 - that godforsaken year when it seemed like every day brought with it some fresh tragedy to endure - I found out that I had a malignant tumor in my left leg. I had been having problems with pain and mobility in my foot and my leg for a year and a half by this point, and after going through a year with the misdiagnosis of it being a cyst, I now knew that it was instead a synovial sarcoma. Synovial sarcomas are incredibly rare, with about three hundred cases a year in the United States, literally a one-in-a-million chance. I really felt SEKs absence then, because who else would have grasped the bizarre cosmic irony of the situation? I told relatively few people about my condition, wanting to keep my cards close to the vest until I knew how things would turn out. Thankfully, synovial sarcoma is a form of cancer that responds quite well to ...
Synovial sarcoma is a malignant, predominantly juxta-articular, soft-tissue tumour representing approximately 10% of all soft-tissue sarcomas. Frequently initially incorrectly diagnosed as a benign lesion, it should be considered as a diagnosis when a young adult patient presents with a calcified juxta-articular soft-tissue mass of insidious onset.
Synovial Sarcoma Survivors is an Online Support Group for people affected with sarcoma. The community guides members on understanding their diagnosis, symptoms, and treatment options.
NY-ESO-1 SPEAR T-cell therapy showed promising results and was reasonably safe in patients with synovial sarcoma, according to a new study. The addition of fludarabine may be important to achieving those positive results. 1
My journey: Living with and overcoming Synovial Sarcoma. A rare and nasty Cancer. Not a how-to guide but ideas and observations during my experience so far. There are only a few SS survivors publishing and Ive found their information helpful and reassuring. The site is also to update my wonderful supporters on my progress. Image above was pre-diagnosis by my daughter of the Alien Baby. This tumour has been removed but the battle to eradicate the disease continues.. ...
My journey: Living with and overcoming Synovial Sarcoma. A rare and nasty Cancer. Not a how-to guide but ideas and observations during my experience so far. There are only a few SS survivors publishing and Ive found their information helpful and reassuring. The site is also to update my wonderful supporters on my progress. Image above was pre-diagnosis by my daughter of the Alien Baby. This tumour has been removed but the battle to eradicate the disease continues.. ...
Hi there, I was diagnosed about 2 years ago with synovial sarcoma, primary in lung with brain mets. I am 38, have 2 kids and wonderful husband. I am told that its quite rare type of cancer, these days cancer in one form or another seem very common to me does it really matter what it is or where it came from, it all sucks. I try to live each day as it comes and have modified our lifestyle to accomodate as much life as possible. Earlier in my diagnosis i was asked my a less than compassionate ex husband, how long I had? I wish at the time my brain was functioning better I would have asked him the same question back, how long do any of us have? the real question is what do we do with the time we are given? I try to appreciate each day and teach my kids to be compassionate and responsible and to enjoy life. Sometimes thats a hard thing to do. Thanks for reading and would love to chat anytime. ...
Because soft tissue sarcomas are rare, they are best diagnosed and treated by a multidisciplinary team of experts with extensive experience in managing these tumors. The soft tissue sarcoma team at UCSF includes surgeons, medical oncologists, radiation oncologists, pathologists, radiologists and other clinicians. The group formulates individualized treatment plans for each patient using precision medicine techniques. UCSF is also on the forefront of research for new therapies, conducting clinical trials for sarcoma using the most promising targeted therapies.. Synovial sarcoma, also known as malignant synovioma, is a rare form of cancer that occurs in the soft tissues of the body. The name "synovial sarcoma" was coined early in the 20th century, as some researchers thought that the microscopic similarity of some tumors to synovium, and its propensity to arise adjacent to joints, indicated a synovial origin; however, the actual cells from which the tumor develops are unknown and not necessarily ...
Malignant tumor of the tissue around the joints. The most common location for the tumor is the knee. Tends to occur in young adults.
Synovial sarcoma (SS) is an aggressive soft tissue malignancy of children and young adults, with no effective systemic therapies. Its specific oncogene, SYT-SSX (SS18-SSX), drives sarcoma initiation and development. The exact mechanism of SYT-SSX oncogenic function remains unknown. In a SYT-SSX2 transgenic model, we show that a constitutive Wnt/β-catenin signal is aberrantly activated by SYT-SSX2, and inhibition of Wnt signaling through the genetic loss of β-catenin blocks SS tumor formation. In a combination of cell-based and SS tumor xenograft models, we show that inhibition of the Wnt cascade through co-receptor blockade and the use of small molecule CK1α activators arrests SS tumor growth. We find that upregulation of the Wnt/β-catenin cascade by SYT-SSX2 correlates with its nuclear reprogramming function. These studies reveal the central role of Wnt/β-catenin signaling in SYT-SSX2-induced sarcoma genesis, and open new venues for the development of effective SS curative agents. ...
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
Patients who have a confirmed response, or have stable disease for ,3 months then progress may receive a 2nd T cell infusion, provided eligibility criteria are met. The 2nd treatment cell infusion will be administered in the same manner as the first. Patients who meet the eligibility criteria may receive a 2nd infusion of NY-ESO-1ᶜ²⁵⁹T no sooner than 60 days and no later than 2 years following completion of the first treatment ...
Rabbit ,200 µg/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.AB2, 36-3269
p>The checksum is a form of redundancy check that is calculated from the sequence. It is useful for tracking sequence updates.,/p> ,p>It should be noted that while, in theory, two different sequences could have the same checksum value, the likelihood that this would happen is extremely low.,/p> ,p>However UniProtKB may contain entries with identical sequences in case of multiple genes (paralogs).,/p> ,p>The checksum is computed as the sequence 64-bit Cyclic Redundancy Check value (CRC64) using the generator polynomial: x,sup>64,/sup> + x,sup>4,/sup> + x,sup>3,/sup> + x + 1. The algorithm is described in the ISO 3309 standard. ,/p> ,p class="publication">Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.,br /> ,strong>Cyclic redundancy and other checksums,/strong>,br /> ,a href="http://www.nrbook.com/b/bookcpdf.php">Numerical recipes in C 2nd ed., pp896-902, Cambridge University Press (1993),/a>),/p> Checksum:i ...
SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional…
SSX5 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional…
You are still only a few days out of surgery so do take things easy, but yet they told me it was important to get up and walk several times a day to help in healing. I had people visit me the first several days and it was kind of annoying because talking was difficult for me too, but it will get easier. I was also told to take breaths in through my nose, hold for a few seconds (increasing as tolerated) then slowly breathe out through your mouth. I dont tolerate pain meds well either but did take oxycodone during the first week + just at night, but, now Im ok with just an occasional tylenol. I really noticed feeling better at the two-week mark, so be patient and take it slow.. Pathology does usually take a couple days and the waiting is difficult. I had chemo 4 years ago at my initial diagnosis and will be getting the same mix of "poison" I had before. I was really sick at the time and had a rough time, but other than healing from this recent surgery, I feel stronger now so am hoping to manage ...
Next-day shipping cDNA ORF clones derived from ssx2ip synovial sarcoma, X breakpoint 2 interacting protein available at GenScript, starting from $99.00.
That was a Friday.. "I got a phone call on Monday," he said.. The news was very bad: a rare deadly cancer - synovial sarcoma.. "Within hours I had to process all this information," he said. "I Googled and researched. I was not taking it lightly.". The result was amputation of his right leg just below the knee. He said he worked on his recovery in small stages and became well enough and comfortable enough with his prosthesis to compete in a triathlon nine months after the amputation. And about one year after the surgery, he sent an audition tape to CBS to apply for a spot on Survivor.. Although he didnt win the money, he took away from the 27 grueling days on the island a chance to break the preconceptions about an amputees physical abilities. Now, he travels as an inspirational speaker and works with Challenges Athletes Foundation, Sarcoma Alliance and Adaptive Action Sports. ...
Primary pleura pulmonary synovial sarcoma - A report of two cases and review of literature. South Asian Journal of Cancer. DOI:10.4103/2278-330X.119933. October-December 2013 Volume 2 Issue 4 Page Nos. 187-296.. ...
Tracy Milner has not had an easy four years. Four times shes faced a doctor who delivered grave news. Cancer. Three of those times, she has gone through treatments and/or surgeries. Now, shes facing what some may call Goliath again. Milner has a rare, soft-tissue cancer known as synovial sarcoma.